Business Context and Reporting Period
This Form 8-K Current Report from Kalaris Therapeutics, Inc. (KLRS) covers events occurring on April 8, 2026. The filing addresses a significant change in executive leadership within the finance department.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
- Resignation of CFO: Matthew Gall resigned as Chief Financial Officer, effective April 14, 2026.
- Appointment of Principal Financial Officer: Brett Hagen, currently the Chief Accounting Officer, was appointed to serve as the Principal Financial Officer effective April 14, 2026.
Management Commentary and Risks
Mr. Hagen has served as Chief Accounting Officer since January 2019 and brings prior experience from Eloxx Pharmaceuticals, Proteostasis Therapeutics, and BIND Therapeutics. The filing explicitly states there have been no changes to Mr. Hagen's compensatory plans or arrangements in connection with this appointment. No specific risks, contingencies, or unusual items were disclosed in this report.
Investor Verification Checklist
- Confirm the effective date of the CFO transition (April 14, 2026).
- Verify the interim financial leadership structure under Brett Hagen.
- Review subsequent filings for any new CFO appointment or changes to the compensation committee.
- Check for any undisclosed reasons for Mr. Gall's departure in future disclosures.